In their comment published in the previous edition of the Journal, Evans and Pereira Gray (2014) refer to a number of issues, including the application of the term “scandal” to the state of care for people with diabetes in primary care and the bundling of care processes measured in the Quality and Outcomes Framework into one composite indicator. We are grateful for this opportunity to respond and contribute to this debate.
The National Diabetes Audit (NDA) has, since its inception in 2004, reported annually on the completion of the NICE-recommended care processes individually and as a care bundle. It has also reported on the achievement of the NICE-recommended intermediate outcome targets for blood pressure, HbA1c and cholesterol, both individually and as a composite.
The National Audit Office (NAO) was tasked by the Public Accounts Committee of the House of Commons to report on diabetes care in England and its report was published in 2012 (NAO, 2012). It concluded that diabetes care needed to improve and cited the evidence that less than half of everyone with diabetes had received all the NICE-recommended care processes. It is probable that the application of the word “scandal” to diabetes care in England may have originated from commentary on this NAO report.
What has not received widespread publicity is that the completion of nine care processes as recorded by the NDA has risen from 6% in 2004 to 46% in 2010–11 (Gadsby and Young, 2013). In 2011–12, the NDA dropped retinal screening from the “bundle” and now reports that 60% of all people with diabetes have achieved all eight care processes, which is a remarkable achievement and is among the best care process delivery results published in the world (Health and Social Care Information Centre, 2014). Diabetes care in England has recently been ranked the fourth best of 30 countries in a pan-European survey (Health Consumer Powerhouse, 2014).
However, the creditable average scores conceal a two-fold difference in care bundle achievement between practices operating in similar geographical areas, which suggests that the NDA is identifying not only long-term “whole system” improvements but also ongoing differences in local care delivery. If the bottom 25% of practices were to be supported and encouraged to achieve care processes delivery rates that “average” practices already achieve, our results would be the best in the world.
The NAO favoured a care composite bundle. This may be felt to be an imperfect measure, but it seems that it is the one that we are stuck with. The intermediate outcome indicators for blood pressure, HbA1c and cholesterol reported separately and as a composite also provide useful information on the quality of diabetes care, and we feel that these results, which demonstrate similar patterns of variation, should also be highlighted.
The NDA shows that diabetes care in England is not a “scandal”. Indeed it is among the best in the world. However, in our view, that should not absolve us of the need to address an ongoing two-fold variation in achievement between the best and worst practices.
Diabetes &
Primary Care
Issue:
Vol:16 | No:06
Measuring diabetes care quality in general practice: How are we doing?
In their comment published in the previous edition of the Journal, Evans and Pereira Gray (2014) refer to a number of issues, including the application of the term “scandal” to the state of care for people with diabetes in primary care and the bundling of care processes measured in the Quality and Outcomes Framework into one composite indicator. We are grateful for this opportunity to respond and contribute to this debate.
The National Diabetes Audit (NDA) has, since its inception in 2004, reported annually on the completion of the NICE-recommended care processes individually and as a care bundle. It has also reported on the achievement of the NICE-recommended intermediate outcome targets for blood pressure, HbA1c and cholesterol, both individually and as a composite.
The National Audit Office (NAO) was tasked by the Public Accounts Committee of the House of Commons to report on diabetes care in England and its report was published in 2012 (NAO, 2012). It concluded that diabetes care needed to improve and cited the evidence that less than half of everyone with diabetes had received all the NICE-recommended care processes. It is probable that the application of the word “scandal” to diabetes care in England may have originated from commentary on this NAO report.
What has not received widespread publicity is that the completion of nine care processes as recorded by the NDA has risen from 6% in 2004 to 46% in 2010–11 (Gadsby and Young, 2013). In 2011–12, the NDA dropped retinal screening from the “bundle” and now reports that 60% of all people with diabetes have achieved all eight care processes, which is a remarkable achievement and is among the best care process delivery results published in the world (Health and Social Care Information Centre, 2014). Diabetes care in England has recently been ranked the fourth best of 30 countries in a pan-European survey (Health Consumer Powerhouse, 2014).
However, the creditable average scores conceal a two-fold difference in care bundle achievement between practices operating in similar geographical areas, which suggests that the NDA is identifying not only long-term “whole system” improvements but also ongoing differences in local care delivery. If the bottom 25% of practices were to be supported and encouraged to achieve care processes delivery rates that “average” practices already achieve, our results would be the best in the world.
The NAO favoured a care composite bundle. This may be felt to be an imperfect measure, but it seems that it is the one that we are stuck with. The intermediate outcome indicators for blood pressure, HbA1c and cholesterol reported separately and as a composite also provide useful information on the quality of diabetes care, and we feel that these results, which demonstrate similar patterns of variation, should also be highlighted.
The NDA shows that diabetes care in England is not a “scandal”. Indeed it is among the best in the world. However, in our view, that should not absolve us of the need to address an ongoing two-fold variation in achievement between the best and worst practices.
In their comment published in the previous edition of the Journal, Evans and Pereira Gray (2014) refer to a number of issues, including the application of the term “scandal” to the state of care for people with diabetes in primary care and the bundling of care processes measured in the Quality and Outcomes Framework into one composite indicator. We are grateful for this opportunity to respond and contribute to this debate.
The National Diabetes Audit (NDA) has, since its inception in 2004, reported annually on the completion of the NICE-recommended care processes individually and as a care bundle. It has also reported on the achievement of the NICE-recommended intermediate outcome targets for blood pressure, HbA1c and cholesterol, both individually and as a composite.
The National Audit Office (NAO) was tasked by the Public Accounts Committee of the House of Commons to report on diabetes care in England and its report was published in 2012 (NAO, 2012). It concluded that diabetes care needed to improve and cited the evidence that less than half of everyone with diabetes had received all the NICE-recommended care processes. It is probable that the application of the word “scandal” to diabetes care in England may have originated from commentary on this NAO report.
What has not received widespread publicity is that the completion of nine care processes as recorded by the NDA has risen from 6% in 2004 to 46% in 2010–11 (Gadsby and Young, 2013). In 2011–12, the NDA dropped retinal screening from the “bundle” and now reports that 60% of all people with diabetes have achieved all eight care processes, which is a remarkable achievement and is among the best care process delivery results published in the world (Health and Social Care Information Centre, 2014). Diabetes care in England has recently been ranked the fourth best of 30 countries in a pan-European survey (Health Consumer Powerhouse, 2014).
However, the creditable average scores conceal a two-fold difference in care bundle achievement between practices operating in similar geographical areas, which suggests that the NDA is identifying not only long-term “whole system” improvements but also ongoing differences in local care delivery. If the bottom 25% of practices were to be supported and encouraged to achieve care processes delivery rates that “average” practices already achieve, our results would be the best in the world.
The NAO favoured a care composite bundle. This may be felt to be an imperfect measure, but it seems that it is the one that we are stuck with. The intermediate outcome indicators for blood pressure, HbA1c and cholesterol reported separately and as a composite also provide useful information on the quality of diabetes care, and we feel that these results, which demonstrate similar patterns of variation, should also be highlighted.
The NDA shows that diabetes care in England is not a “scandal”. Indeed it is among the best in the world. However, in our view, that should not absolve us of the need to address an ongoing two-fold variation in achievement between the best and worst practices.
Evans P, Pereira Gray D (2014) Measuring diabetes care quality in general practice: A whole bundle of trouble? Diabetes & Primary Care 16: 236
Gadsby R, Young B (2013) Diabetes care in England and Wales: information from the 2010–2011 National Diabetes Audit. Diabet Med 30: 799–802
Health and Social Care Information Centre (2014) National Diabetes Audit 2012–2013. Report 1: Care Processes and Treatment Targets. HSCIC, Leeds. Available at: http://bit.ly/1mTWjub (accessed 12.11.2014)
Health Consumer Powerhouse (2014) Euro Diabetes Index 2014. Available at: http://bit.ly/14dyipO (accessed 12.11.2014)
National Audit Office (2012) The management of adult diabetes services in the NHS. Department of Health, London. Available at: http://bit.ly/1dxUrMe (accessed 12.11.2014)
Conference over coffee: Diabetes and obesity initiatives, multiple long-term condition management and the bookends of pregnancy
Scottish Government and NHS Scotland consensus statement on GLP-1-based therapies for obesity
Editorial: Type 2 diabetes, CVD, CKD, dementia and health inequality: Adopting a preventative approach
The dialysis timebomb: Why preventing kidney disease is everyone’s responsibility
Conference over coffee: Oncology, end-of-life care, psychology and insulin dilemmas
How to follow up gestational diabetes
Prescribing pearls: A guide to pioglitazone
Bite-size practice points from the 2024 PCDS National Conference.
22 Nov 2024
Scotland-wide advice to inform the process of making injectable weight management drugs available and to prevent variation between Health Boards.
14 Nov 2024
Jane Diggle discusses points for our practice that can help prevent all of these conditions, as well as improve equity of care.
13 Nov 2024
The key role of primary care in avoiding a four-fold increase in the number of people needing dialysis by 2035.
13 Nov 2024